Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin
Kotyla, P.J.; Sliwinska-Kotyla, B.; Kucharz, E.J.
Journal of rheumatology 33(11): 2361-3; author reply 2363
2006
ISSN/ISBN: 0315-162X PMID: 17086617 Document Number: 604802
Document emailed within 1 workday
Related Documents
Krichevskaia, O.A.; Kliukvina, N.G.; Aleksandrova, E.N.; Samsonov, M.I.; Nasonov, E.L. 2004: Clinical value of soluble tumor necrosis factor-alpha receptors in patients with systemic lupus erythematosus Klinicheskaia Meditsina 82(10): 51-55Robak, E.; Sysa-Jedrzejewska, A.; Dziankowska, B.; Torzecka, D.; Chojnowski, K.; Robak, T. 1998: Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity Archivum Immunologiae et Therapiae Experimentalis 46(6): 375-380
Lu, L.-Y.; Cheng, H.-H.; Sung, P.-K.; Tai, M.-H.; Yeh, J.-J.; Chen, A. 2005: Tumor necrosis factor-beta +252A polymorphism is associated with systemic lupus erythematosus in Taiwan Journal of the Formosan Medical Association 104(8): 563-570
Kaneko, H.; Yamada, H.; Mizuno, S.; Udagawa, T.; Kazumi, Y.; Sekikawa, K.; Sugawara, I. 1999: Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice Laboratory Investigation; a Journal of Technical Methods and Pathology 79(4): 379-386
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Dubois, E.L.; Chandor, S.; Friou, G.J.; Bischel, M. 1971: Progressive systemic sclerosis and localized scleroderma morphea with positive lupus erythematosus cell test and unusual systemic manifestations compatible with systemic lupus erythematosus presentation of 14 cases including 1 set of identical twins 1 with scleroderma and the other with systemic lupus erythematosus review of the literature Medicine (Baltimore) 50(3): 199-222
Gad, H.I. 2013: The potential role of anti tumor necrosis factor-alpha antibodies on some renal functions and vasoregulatory factors in preeclamptic pregnant Wistar rats Saudi Medical Journal 34(5): 490-496
Abou-Raya, A.; el-Hallous, D.; Fayed, H. 2004: 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus Clinical and Investigative Medicine. Medecine Clinique et Experimentale 27(6): 306-311
Dayer, J.-M. 2002: Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? Journal of Rheumatology. Suppl 65: 10-15
Incaprera, M.; Rindi, L.; Bazzichi, A.; Garzelli, C. 1998: Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity Clinical and Experimental Rheumatology 16(3): 289-294
Bendtzen, K.; Hansen, P.R.; Rieneck, K. 2004: Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor-alpha and interferon-gamma and has potential effect in the treatment of arthritis Ugeskrift for Laeger 166(37): 3203-3207
Broudy, V.C.; Harlan, J.M.; Adamson, J.W. 1987: Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells Journal of Immunology 138(12): 4298-4302
Alsalameh, S.; Mattka, B.; Al-Ward, R.; Lorenz, H.M.; Manger, B.; Pfizenmaier, K.; Grell, M.; Kalden, J.R. 1999: Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor Journal of Rheumatology 26(3): 645-653
Kawakami, M.; Kitani, A.; Hara, M.; Harigai, M.; Suzuki, K.; Kawaguchi, Y.; Ishii, H.; Kazama, M.; Kawagoe, M.; Nakamura, H. 1992: Plasma thrombomodulin and alpha 2-plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus Journal of Rheumatology 19(11): 1704-1709
Serwin, A.B.; Flisiak, I.; Chodynicka, B. 2004: The role of tumor necrosis factor alpha receptors (TNF-alpha) in psoriasis and other skin disorders Wiadomosci Lekarskie 57(11-12): 686-690
Girolomoni, G.; Pastore, S.; Albanesi, C.; Cavani, A. 2002: Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases Current Opinion in Investigational Drugs 3(11): 1590-1595
Giannini, S.D.; de Góes, J.M.; Dereviack, B.E.; Machado, C.; Forti, N.; Diament, J. 1990: Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis Arquivos Brasileiros de Cardiologia 54(6): 407-414
Bebök, Z.; Szekeres, G.; Horváth, G.; Duda, E.; Németh, P. 1993: Creation of monoclonal antibodies against tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor alpha (TFG-alpha), their definition and possible use Orvosi Hetilap 134(24): 1303-1307
Billings, R.E.; Chen, S.A.; Hollenbach, S.; Amman, A.; Patzer, E.; Hobson, W.; McCalden, T.A. 1990: The role of tumor necrosis factor-alpha in endotoxin shock Proceedings of the Western Pharmacology Society 33: 117-121
Leibowitz, G.; Ben-Yehuda, A.; Naparstek, Y. 1990: Role of plasmapheresis in the treatment of systemic lupus erythematosus Harefuah 118(6): 329-333